Investing.com - Y mAbs Therapeutics (NASDAQ: YMAB) reported third quarter EPS of $-0.16, $0.01 worse than the analyst estimate of $-0.15. Revenue for the quarter came in at $18.46M versus the consensus estimate of $23.56M.
Guidance
Y mAbs Therapeutics sees FY 2024 revenue of $87.00M-$95.00M versus the analyst consensus of $91.66M.
Y mAbs Therapeutics's stock price closed at $15.55. It is up 38.72% in the last 3 months and up 204.90% in the last 12 months.
Y mAbs Therapeutics saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Y mAbs Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Y mAbs Therapeutics's Financial Health score is "good performance".
Check out Y mAbs Therapeutics's recent earnings performance, and Y mAbs Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar